Realdiron® is used for intramuscular or subcutaneous administration, dissolving immediately before use the contents of the vial or ampoule in 1 ml of water for injection.The drug dissolves quickly, regardless of the dose contained in the vial or ampoule. The drug solution is a colorless, transparent or slightly opalescent liquid. Realdiron® does not contain preservatives, so only freshly prepared solution should be used to avoid bacterial contamination.
Viral diseases:
When acute hepatitis B (light, medium-heavy and severe forms) Realdiron® is injected into 1 million ME twice a day for 5-6 days, then the dose is reduced to 1 million ME per day and injected for another 5 days. If necessary (after controlling biochemical blood tests to assess the functional state of the liver), treatment can continue for another 2 weeks, during which the drug is administered 1 million ME two times a week.
Realdiron® is most effective at the beginning of icteric period before the 5th day of jaundice, in later periods, the administration of the drug is less effective. Realdiron® is not effective in developing hepatic coma and cholestatic course of the disease.
When chronic active hepatitis B the drug is prescribed for 3-6 million ME three times a week for 24 weeks.If after administration of the drug for 12 weeks there is no clinical, biochemical improvement and / or disappearance HBsAg, treatment with Rehldironum is canceled.
When chronic hepatitis C The drug is prescribed by 3 million ME three times a week for 24 weeks. If after administration of the drug for 4 weeks, there is no 50% reduction in ALT activity in the blood plasma, the dose of the drug is increased to 6 million ME three times per week. Treatment with Rehldironum is terminated if, after 12 weeks of the drug, there is no clinical, biochemical improvement.
When Tick-borne encephalitis. With meningeal forms of tick-borne encephalitis, the drug is administered for 1-3 million ME twice a day for 10 days. Then appoint supportive treatment - five injections of 1-3 million ME every 2 days.
Oncological diseases:
The instructions contain recommended therapeutic doses of Realdirone®. The general principle of the use of interferon in cancer is to prescribe the maximum dose that the patient can tolerate for a sufficiently long period of time (months and years). As interferon alfa has a cytostatic effect that supports treatment with Realdiron should continue after reaching an objective effect - hematological remission, regression of solid tumor sites.
When hairy cell leukemia Realdiron® is administered for 3 million ME daily. After achieving hematologic remission, support therapy is transferred to 3 million ME three times a week for two months and further treatment can not continue. When relapse treatment is repeated.
When chronic myelogenous leukemia Realdiron® is administered for 9 million ME daily. After achieving hematologic remission, supportive treatment for 9 million ME three times per week. The duration of treatment is determined by the attending physician and depends on the nature of the course of the disease.
When renal cell carcinoma Realdiron® is injected into 18 million ME three times per week. Objective effect (complete or partial regression of metastases) occurs after 8-12 weeks of treatment with Rehlildiron or at a later date. When the therapeutic effect or stabilization of the disease is achieved, maintenance therapy of 18 million ME three times per week.The duration of treatment is determined by the attending physician and depends on the nature of the course of the disease. With the progression of the process, treatment with the drug can be replaced by the attending physician for antitumor therapy.
When sarcoma Kaposi against AIDS the drug is administered daily for 36 million ME. The drug is used for a long time, except for cases of rapid progression of the disease or severe intolerance. After the manifestation of the effect, a maintenance therapy of 18 million ME three times per week.
When cutaneous T-cell lymphoma (mushroom mycosis and Cesari syndrome)
prescribe Realdiron® for 18 million ME daily. The duration of treatment is determined by the attending physician and depends on the nature of the course of the disease.
When malignant melanoma Realdiron® is injected into 18 million ME daily. After achieving an objective effect (complete or partial regression of metastases), supportive therapy for 18 million ME three times per week. Adjuvant therapy Realdiron for 18 million ME three times a week, prescribed after surgical removal of the primary tumor of melanoma I-II stage or metastases to the regional lymph nodes, contributes to an increase in the duration of remission and the survival of patients.